GEAN — Genetic Analysis As Share Price
Last trade - 00:00- NOK20.63m
- NOK9.78m
- NOK14.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.64 | ||
| Price to Tang. Book | 1.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.46 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.66% | ||
| Return on Equity | -62.57% | ||
| Operating Margin | -168.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 7.29 | 5.78 | 6.8 | 11.16 | 14.15 | 59.39 | 74.24 | 28.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genetic Analysis AS is a Norway-based company active in the field of molecular diagnostics of diseases related to large and small intestine (gut) imbalances. The Company has developed a DNA-based platform technology that allows for simultaneous analysis of a number of similar (but not identical) gene fragments in one reaction. The GA-map platform technology utilizes common and variable DNA sequences within the 16S rRNA gene of the bacteria to characterize and identify the different bacteria. The technology makes it possible to generate profiles of a person's microbiota and correlate that profile to different health conditions.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 26th, 2009
- Public Since
- October 1st, 2021
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- AktieTorget Stock Exchange
- Shares in Issue
- 38,199,319
- Address
- Kabelgata 8, OSLO, 0580
- Web
- https://www.genetic-analysis.com/
- Phone
- Auditors
- PricewaterhouseCoopers AS
FAQ
As of Today at 19:09 UTC, shares in Genetic Analysis As are trading at NOK0.54. This share price information is delayed by 15 minutes.
Shares in Genetic Analysis As last closed at NOK0.54 and the price had moved by -68.7% over the past 365 days. In terms of relative price strength the Genetic Analysis As share price has underperformed the FTSE Global All Cap Index by -70.62% over the past year.
There is no consensus recommendation for this security.
Genetic Analysis As does not currently pay a dividend.
Genetic Analysis As does not currently pay a dividend.
Genetic Analysis As does not currently pay a dividend.
To buy shares in Genetic Analysis As you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK0.54, shares in Genetic Analysis As had a market capitalisation of NOK20.63m.
Here are the trading details for Genetic Analysis As:
- Country of listing: Sweden
- Exchange: AKT
- Ticker Symbol: GEAN
Based on an overall assessment of its quality, value and momentum Genetic Analysis As is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Genetic Analysis As is NOK2.69. That is 397.34% above the last closing price of NOK0.54.
Analysts covering Genetic Analysis As currently have a consensus Earnings Per Share (EPS) forecast of -NOK0.10 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genetic Analysis As. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -53.78%.
As of the last closing price of NOK0.54, shares in Genetic Analysis As were trading -46.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genetic Analysis As PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK0.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Genetic Analysis As' directors